Product logins

Find logins to all Clarivate products below.


Autism Spectrum Disorder – Current Treatment – Treatment Algorithms: Claims Data Analysis – Autism Spectrum Disorder (US)

Autism spectrum disorder (ASD) is a complex, heterogeneous, neurodevelopmental disorder that involves significant social, communicational, and behavioral challenges. Behavioral and developmental therapies are the cornerstones of treatment. There is no cure for ASD, and pharmacological intervention is mainly focused on symptomatic management. Risperidone and aripiprazole are the only two FDA-approved drugs for the treatment of irritability associated with ASD; other drugs, such as antidepressants, stimulants, and antiepileptics, are used off-label to manage co-occurring psychiatric conditions. Our Treatment Algorithms study provides national patient-level claims data to explore the use of key therapies in both newly diagnosed and recently treated patients, providing insight into the current treatment landscape for ASD.

Questions answered

  • What patient shares do key therapies and brands garner by line of therapy in newly diagnosed ASD patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed ASD patients?
  • How have atypical antipsychotics been integrated into the treatment algorithm, and what is their source of business?
  • What percentage of ASD patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
  • What percentage of ASD patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
  • What are the product-level compliance and persistency rates among drug-treated patients?

Product description

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall, using real-world, patient-level claims data, enabling you to:

  • Understand patient flow between lines of therapy.
  • Evaluate your brand share against competitors.
  • Accurately assess your source of business.
  • Quantify opportunities at different stages of the treatment algorithm.

Product enhancement

Treatment Algorithms: Claims Data Analysis leverages Clarivate’s proprietary Real-World Data, which brings larger patient samples, broader payer coverage, and faster availability for more robust and timely analyses. Additionally, we include new patient demographic analyses: age, gender, ethnicity, and region.

Content highlights

Publication date: April 2026

Geography: United States

Real-world data: U.S. pharmacy and medical claims data

Key drugs covered: Risperidone, aripiprazole, sertraline, methylphenidate HCl, fluoxetine

Key analyses:

  • Brand / therapy usage across longitudinal patient sample
  • Newly diagnosed patient analysis
  • Treatment initiation and progression
  • Line of therapy analysis
  • Combination therapy analysis
  • Source of business for recently treated patients
  • Persistency and compliance analysis
  • Product-level patient flow

Related Market Assessment Reports

Report
Endometrial Cancer – Landscape & Forecast – Disease Landscape & Forecast (G7)
The treatment landscape for endometrial carcinoma is undergoing rapid transformation, fueled by the increasing use of immune checkpoint inhibitors and advances in molecular classification. In the…
Report
Breast Cancer – Unmet Need – Unmet Need – Metastatic HR-Positive / HER2-Negative Breast Cancer (US/EU)
The landscape of advanced HR-positive / HER2-negative breast cancer treatment is continually evolving. CDK4/6 inhibitors (Pfizer’s Ibrance, Novartis’s Kisqali, and Eli Lilly’s Verzenio)…
Report
Schizophrenia – Landscape & Forecast – Disease Landscape & Forecast (G7)
The schizophrenia therapy market remains very competitive; atypical and typical antipsychotics play a dominant role. While the continued generic erosion of atypical antipsychotics influences…
Report
Hepatitis B Virus – Geographic Focus: China – China In-Depth – Hepatitis B Virus
HBV is a major public health burden in China, with chronically infected individuals at a significantly increased risk of developing hepatic cirrhosis and hepatocellular carcinoma. Current treatment…
Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Landscape & Forecast – Disease Landscape & Forecast (G7)
The non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL) therapy market is rapidly evolving as novel agents provide alternatives to conventional chemoimmunotherapy regimens. This…